In Q4 2025, Penumbra generated revenue of 385385000 and net income of 47343000, reflecting 22.1% year-over-year growth, margin expansion, and strong performance across thrombectomy and embolization and access products.

Penumbra, Inc. delivered a robust third quarter in 2025, with total revenue increasing by 17.8% to $354.7 million. The company saw strong growth in both its thrombectomy and embolization and access product lines, particularly in the United States. Gross profit and income from operations also showed healthy increases compared to the prior year.

Penumbra reported a 13.4% year-over-year revenue increase in Q2 2025, with solid gains in both thrombectomy and embolization segments, along with significant improvement in operating margins and profitability.

Penumbra, Inc. delivered solid Q1 2025 results driven by strong thrombectomy product performance in the U.S., achieving significant revenue growth and expanding profitability metrics.

Penumbra's Q4 2024 revenue grew 10.8% YoY to $315.52 million, driven by strong U.S. thrombectomy sales (+27.3% YoY). Net income decreased by 37.85% YoY to $33.68 million. Gross margin improved to 66.8%, while operating margin expanded to 13.6%. International revenue declined 16.5% YoY due to lower sales in China.

Penumbra, Inc. reported an 11.1% increase in revenue to $301.0 million for the third quarter of 2024. The U.S. thrombectomy revenue grew by 21.2%. Net income was $29.5 million, with an adjusted EBITDA of $56.7 million.

Penumbra, Inc. reported a 14.5% increase in revenue to $299.4 million for Q2 2024. The company experienced a loss from operations of $81.0 million, including $110.3 million in one-time non-cash impairment charges. Adjusted EBITDA was $46.3 million, with an adjusted EBITDA margin of 15.5%.

Penumbra, Inc. reported a 15.4% increase in revenue to $278.7 million for Q1 2024, driven by a 35.2% increase in U.S. thrombectomy revenue. The company's adjusted EBITDA was $37.6 million with a margin of 13.5%.

Penumbra, Inc. reported a strong fourth quarter in 2023, with revenue reaching $284.7 million, a 28.7% increase compared to Q4 2022. The company's thrombectomy product sales grew significantly, driving overall revenue growth. Penumbra is strategically shifting its product revenue categories to provide more meaningful insights to investors.

Penumbra, Inc. reported a 26.8% increase in revenue to $270.9 million for Q3 2023, driven by strong growth in thrombectomy products. The company achieved a net income of $9.2 million and an adjusted EBITDA of $51.5 million.

Penumbra, Inc. reported a strong second quarter with a 25.5% increase in revenue, reaching $261.5 million. The company's income from operations turned positive, reaching $17.9 million, compared to a loss in the same quarter last year. They are also increasing their revenue guidance for the year.

Penumbra, Inc. reported financial results for the first quarter ended March 31, 2023, with total revenue increasing to $241.4 million, an 18.4% increase compared to the first quarter of 2022. The company reported a net income of $8.6 million, a significant improvement from the $0.1 million net income in the same period last year.

Penumbra, Inc. reported financial results for the fourth quarter and full year ended December 31, 2022. Total revenue increased to $221.2 million for the fourth quarter of 2022 compared to $204.0 million for the fourth quarter of 2021, an increase of 8.4%, or 10.5% in constant currency.

Penumbra, Inc. reported a 12.4% increase in revenue, reaching $213.7 million in the third quarter of 2022 compared to the third quarter of 2021.

Penumbra, Inc. reported a revenue increase of 13.1% in the second quarter of 2022, reaching $208.3 million. Vascular products and international sales were key growth drivers. The company is maintaining its full-year revenue guidance of $860 million to $875 million.

Penumbra, Inc. reported financial results for the first quarter ended March 31, 2022, with revenue of $203.9 million, an increase of 20.5% compared to the first quarter of 2021.

Penumbra, Inc. reported a revenue of $204.0 million for the fourth quarter of 2021, representing a 22.2% increase compared to the fourth quarter of 2020. The company's gross profit for the quarter was $125.4 million, or 61.5% of total revenue.

Penumbra, Inc. reported financial results for the third quarter ended September 30, 2021, with revenue reaching $190.1 million, a 25.8% increase compared to the third quarter of 2020. The company is increasing its guidance for 2021 total revenue to be in the range of $735 million to $740 million.

Penumbra, Inc. reported a strong second quarter with a 75.3% increase in revenue compared to the previous year, reaching $184.3 million. The company achieved an operating income of $10.3 million, a significant improvement from the operating loss in the same quarter of the previous year. The company is increasing its guidance for 2021 total revenue to be in the range of $720 million to $730 million.

Penumbra, Inc. reported a revenue of $169.2 million in the first quarter of 2021, representing a 23.2% increase compared to the first quarter of 2020. The company's vascular product sales grew by 50.5%, while neuro product sales increased by 2.5%.

Penumbra, Inc. reported its Q4 and Full Year 2020 financial results, with Q4 revenue reaching $166.9 million, a 14.9% increase compared to Q4 2019. The company's US revenue for Q4 2020 was $116.8 million, 21.6% above the same period a year ago. Gross profit for the quarter was $94.3 million, or 56.5% of total revenue.

Penumbra, Inc. reported a revenue of $151.1 million for the third quarter of 2020, representing an 8.3% increase compared to the third quarter of 2019. The company experienced growth in US revenue, particularly in vascular products, while facing declines in international and neuro product revenues. Operating loss for the quarter was $20.2 million.

Penumbra, Inc. reported a decrease in revenue of 21.7% compared to the second quarter of 2019. The company experienced an operating loss of $17.6 million, compared to an operating income of $12.8 million for the second quarter of 2019.

Penumbra, Inc. reported a 6.9% increase in revenue for the first quarter of 2020, reaching $137.3 million. The growth was primarily driven by vascular products, while neuro products experienced a slight decline. Operating income decreased compared to the previous year.

Penumbra, Inc. reported a 20.3% increase in revenue for the fourth quarter of 2019, reaching $145.3 million. The company's operating income also rose to $10.6 million, compared to $6.7 million in the same period of the previous year. Full year revenue grew by 23.0% to $547.4 million.